In Vitro Diagnostics Market to Witness Swift Growth
|
By LabMedica International staff writers Posted on 26 May 2016 |
The global in vitro diagnostics (IVD) market is expected to expand rapidly owing to an aging population, chronic lifestyle related diseases, and increased usage of personalized medicine and point-of-care (POC) testing. These are the latest findings of Grand View Research (San Francisco, CA, USA), a market research and consulting company.
Applications of IVD include oncology, cancer, nephrology, cardiology, drug testing, autoimmune diseases, diabetes and infectious diseases, with tests being used by a wide range of customers, including academic institutes, hospitals, and laboratories. Home testing is another application resulting from innovations and advancement in various IVD technologies, further enhancing the increasing role of POC disease diagnostics. This, along with the need for identification of malaria and filiarsis pathogens, are some of the key drivers of IVD market.
Increased consumer awareness of serious health issues such as diabetes, cancer, and sexually transmitted diseases are also rapidly altering the healthcare environment, creating a need for point-of-care (POC) recognition and detection of communicable diseases such as respiratory infections, respiratory syncytial virus (RSV), influenza, and pneumonia. Of particular interest is the tissue IVD market, which is expected to rise owing to the increasing incidents of lung and bronchus cancer, melanoma, and prostate breast cancer diagnosis.
Product-wise, the in IVD market is segmented into instruments, services, data management systems, reagents, and kits that are intended to diagnose, cure, prevent, or treat a particular disease. Different techniques are involved, including molecular diagnostics, blood tests, clinical chemistry, microbiological diagnostic techniques, and flow cytometry. The most commonly used technologies include electrolyte and metabolic panels; lipid and renal profiles; hematology, coagulation, and hemostasis microarrays; and radioimmunoassay and specialty chemicals, among others.
In 2014, North America was the largest regional segment, with about 43% market share owing to established distribution channels, extraordinary diagnostics in cancer screening, and prevalent disorders like respiratory diseases and genetic testing. The IVD market in Europe follows the lead and is expected to rise on account of rising cases of cancer, tuberculosis and pneumonia. However, Asia Pacific and China will follow the IVD market trend owing to the rising population and increasing disposable incomes.
Prominent players dominating the global IVD market are Johnson & Johnson (JNJ; New Brunswick, NJ, USA), Siemens Healthcare, BD (Franklin Lakes, NJ, USA), Roche Diagnostics, Abbott Laboratories (Abbot Park, IL, USA), and Beckman Coulter.
Related Links:
Grand View Research
Johnson & Johnson
BD
Abbott Laboratories
Applications of IVD include oncology, cancer, nephrology, cardiology, drug testing, autoimmune diseases, diabetes and infectious diseases, with tests being used by a wide range of customers, including academic institutes, hospitals, and laboratories. Home testing is another application resulting from innovations and advancement in various IVD technologies, further enhancing the increasing role of POC disease diagnostics. This, along with the need for identification of malaria and filiarsis pathogens, are some of the key drivers of IVD market.
Increased consumer awareness of serious health issues such as diabetes, cancer, and sexually transmitted diseases are also rapidly altering the healthcare environment, creating a need for point-of-care (POC) recognition and detection of communicable diseases such as respiratory infections, respiratory syncytial virus (RSV), influenza, and pneumonia. Of particular interest is the tissue IVD market, which is expected to rise owing to the increasing incidents of lung and bronchus cancer, melanoma, and prostate breast cancer diagnosis.
Product-wise, the in IVD market is segmented into instruments, services, data management systems, reagents, and kits that are intended to diagnose, cure, prevent, or treat a particular disease. Different techniques are involved, including molecular diagnostics, blood tests, clinical chemistry, microbiological diagnostic techniques, and flow cytometry. The most commonly used technologies include electrolyte and metabolic panels; lipid and renal profiles; hematology, coagulation, and hemostasis microarrays; and radioimmunoassay and specialty chemicals, among others.
In 2014, North America was the largest regional segment, with about 43% market share owing to established distribution channels, extraordinary diagnostics in cancer screening, and prevalent disorders like respiratory diseases and genetic testing. The IVD market in Europe follows the lead and is expected to rise on account of rising cases of cancer, tuberculosis and pneumonia. However, Asia Pacific and China will follow the IVD market trend owing to the rising population and increasing disposable incomes.
Prominent players dominating the global IVD market are Johnson & Johnson (JNJ; New Brunswick, NJ, USA), Siemens Healthcare, BD (Franklin Lakes, NJ, USA), Roche Diagnostics, Abbott Laboratories (Abbot Park, IL, USA), and Beckman Coulter.
Related Links:
Grand View Research
Johnson & Johnson
BD
Abbott Laboratories
Latest Industry News
- Global Multiplex Assays Market Driven by High-Throughput Diagnostic Demand
- GRAIL Presents Full Results from NHS-Galleri Trial at ASCO 2026
- Global Framework Integrates Digital Pathology for Companion Diagnostic Development
- Werfen and Oxford Nanopore Collaborate on Transplant Assay Development
- New Distribution Agreement Expands Access to CE-Marked Precision Oncology Assays
- ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026
- Artera to Highlight AI-Based Cancer Risk Stratification at ASCO 2026
- Natera to Present Data on MRD-Guided Cancer Care at ASCO 2026
- Fujifilm Integrates Structured Reporting into Digital Pathology Workflow
- Strategic Collaboration Advances RNA Foundation Models for Precision Oncology
- Partnership Brings Single-Cell Analysis into Clinical Oncology Workflows
- Partnership Aims to Bring Risk-Guided CKD Care to Health Systems
- AI-Powered Multi-Functional Analyzer Wins German Innovation Award
- Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
- FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
- CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
In myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), molecular blood testing for minimal residual disease (MRD) can detect signs of impending relapse before clinical symptoms emerge.... Read more
Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
Metastatic prostate cancer remains a major treatment challenge, particularly when deciding whether to add chemotherapy to hormonal therapy. In the United States, about 334,000 men are diagnosed with prostate... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more








